PARTICULARS TO APPEAR ON THE OUTER PACKAGE - Carton

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Drontal Dog Tasty Bone 150/144/50 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

One tablet contains:

150 mg febantel
144 mg pyrantel embonate (equivalent to 50 mg pyrantel)
50 mg praziquantel

3. PACKAGE SIZE

2 tablets
4 tablets
6 tablets
24 tablets
102 tablets
312 tablets

4. TARGET SPECIES

Dogs.

5. INDICATIONS

For products not subject to veterinary prescription
Treatment of mixed infections by roundworms and tapeworms.

6. ROUTES OF ADMINISTRATION

Oral use.
1 tablet per 10 kg (with bone-shaped tablet pictogram/graphic)

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use half tablet within 7 days.

9. SPECIAL STORAGE PRECAUTIONS

Half-tablets should be wrapped in aluminium foil and returned to the open blister.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 08007/5003

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS - Blister Sheets

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Drontal Dog Tasty Bone

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

febantel	150 mg
pyrantel embonate	144 mg
praziquantel	50 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Vetoquinol logo

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Drontal Dog Tasty Bone 150/144/50 mg tablets

2. Composition

Each tablet contains:

Active substances:
150 mg febantel
50 mg pyrantel equivalent to 144 mg pyrantel embonate
50 mg praziquantel

A light-brown to brown, meat flavoured, bone shaped tablet scored on both sides that can be divided into halves.

3. Target species

Dogs.

4. Indications for use

Treatment of mixed infections by nematodes and cestodes of the following species:

Roundworms:
Ascarids (adults and late immature forms): *Toxocara canis, Toxascaris leonina*
Hookworms (adults): *Uncinaria stenocephala, Ancylostoma caninum*
Whipworms (adults): *Trichuris vulpis*

Tapeworms (adult and immature forms): *Echinococcus granulosus*
Echinococcus multilocularis
Dipylidium caninum
Taenia spp.

5. Contraindications

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not use during the 1st and 2nd third of pregnancy (see “Special warnings” section).

6. Special warnings

Special warnings:

Fleas serve as intermediate hosts for one common type of tapeworm - Dipylidium caninum. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.

Special precautions for safe use in the target species:

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

To minimise the risk of reinfestation and new infestation, excreta should be collected and properly disposed of for 24 hours following treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

In the interests of good hygiene, persons administering the product directly to a dog or by adding it to the dog's food should wash their hands afterwards.

Other precautions:

Since it contains praziquantel, the product is effective against Echinococcus spp. which do not occur in all EU member states but are becoming more common in some. Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Pregnancy and lactation:

Teratogenic effects attributed to high doses of febantel administered during early pregnancy have been reported in rats, sheep and dogs.

The safety of the product has not been investigated during the 1st and 2nd third of pregnancy. Do not use in pregnant dogs during the 1st and 2nd third of pregnancy (see "Contraindications" section).

A single treatment during the last third of pregnancy or during lactation has been demonstrated safe.

Interaction with other medicinal products and other forms of interaction:

The anthelmintic effects of this product and piperazine containing products may be antagonized when the two drugs are used together.

Concurrent use with other cholinergic compounds can lead to toxicity.

Overdose:

No signs of adverse reactions were observed in safety studies in dogs and pups folllowing administration of 10 times the recommended dose of the product.

7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorders (e.g., vomiting and diarrhoea)[1] Anorexia (loss of appetite), Lethargy, Hyperactivity.

[1]Mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

For oral administration only.

Dosage

For treatment of dogs, 1 tablet per 10 kg body weight (15 mg febantel, 14.4 mg pyrantel embonate and 5 mg praziquantel/kg body weight).

Dosages are as follows:

Body weight (kg)	Tablet quantity
2-5	½
>5-10	1
>10-15	1 ½
>15-20	2

For each additional 5 kg bodyweight, administer an additional half tablet.

Administration and Duration of Treatment

The tablets are flavoured and studies have shown that they are palatable and are taken voluntarily by the majority of (approximately, 9 of every 10) dogs tested.

Tablets should be given as a single administration.

The advice of a veterinarian should be sought regarding the need for and frequency of repeat treatment.

Not for use in dogs weighing less than 2 kg.

To ensure a correct dosage, body weight should be determined as accurately as possible.

9. Advice on correct administration

The tablets can be administered with or without food. Access to normal diet does not need to be limited before or after treatment.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after Exp. The expiry date refers to the last day of that month.

After opening the blister, remaining half-tablets should be wrapped in aluminium foil and returned to the open blister. Shelf life of half-tablets: 7 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product not subject to prescription

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 08007/5003

Container sizes: Cartons containing 2, 4, 6, 24, 102, 312 tablets.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Vetoquinol UK Limited
Steadings Barn
Pury Hill Business Park, Nr. Alderton
Towcester
Northamptonshire
NN12 7LS
United Kingdom

Manufacturer responsible for batch release:

KVP Pharma und Veterinär Produkte GmbH, Projensdorfer Str. 324, 24106 Kiel, Germany
EUROPHARTECH, 34 rue Henri Matisse, 63370 Lempdes, France

17. Other information

NFA-VPS

Approved 12 May 2026
Gavin Hall